These findings were also confirmed based on clinical cohorts from the Oncomine database, which showed that GC patients with high RBMS1 mRNA levels had lower 3-year and 5-year OS rates than those with low RBMS1 mRNA levels (Fig. 3A–C). Here, RBMS1 is linked to gastric cancer.